According to The Fly, trillium Therpeutc (TR) has received a rating update from a Wall Street analyst today. Analyst Boris Peaker from Cowen & Co. reiterated a Buy rating
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 6.1% and a 40.9% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Read also: AcelRx (ACRX) Tumbles After Stock Offering Prices at Deep Discount
The the analyst consensus on Trillium Therpeutc is currently a Moderate Buy rating.
Trillium Therpeutc’s market cap is currently C$49.23M and has a P/E ratio of 0. The company has a Price to Book ratio of 4.64.
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company, which engages in the development of innovative therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Toronto, Canada.
The company’s shares closed on Tuesday at C$0.19.
